A model for the Dutch pharmaceutical market

E.J.F. Canton, Ed Westerhout

Research output: Contribution to journalArticleScientificpeer-review

Abstract

This paper develops a general‐equilibrium model for the Dutch pharmaceutical market. The model derives the behaviour of patients, pharmacists, drug producers and parallel‐importers from microeconomic principles and recognizes the interactions between the various actors. The latter is important since the general‐equilibrium effects are sometimes at odds with intuition from a partial‐equilibrium approach. A calibrated version of the model is used to evaluate the effects of various policy experiments on the bill for pharmaceutical care in the Netherlands. These experiments include an incentive policy to encourage cost‐conscious drug distribution, an increase of copayments for pharmaceutical care, a reduction of trade barriers for parallel‐importers, and market entry by producers of generic substitutes.
Original languageEnglish
Pages (from-to)391-402
JournalHealth Economics
Volume8
Issue number5
DOIs
Publication statusPublished - Aug 1999
Externally publishedYes

Fingerprint

Pharmaceutical Services
Pharmaceutical Preparations
Intuition
Pharmacists
Netherlands

Cite this

Canton, E.J.F. ; Westerhout, Ed. / A model for the Dutch pharmaceutical market. In: Health Economics. 1999 ; Vol. 8, No. 5. pp. 391-402.
@article{f766a2863d404ca99e2fcd008209f1bf,
title = "A model for the Dutch pharmaceutical market",
abstract = "This paper develops a general‐equilibrium model for the Dutch pharmaceutical market. The model derives the behaviour of patients, pharmacists, drug producers and parallel‐importers from microeconomic principles and recognizes the interactions between the various actors. The latter is important since the general‐equilibrium effects are sometimes at odds with intuition from a partial‐equilibrium approach. A calibrated version of the model is used to evaluate the effects of various policy experiments on the bill for pharmaceutical care in the Netherlands. These experiments include an incentive policy to encourage cost‐conscious drug distribution, an increase of copayments for pharmaceutical care, a reduction of trade barriers for parallel‐importers, and market entry by producers of generic substitutes.",
author = "E.J.F. Canton and Ed Westerhout",
year = "1999",
month = "8",
doi = "10.1002/{\%}28SICI{\%}291099-1050{\%}28199908{\%}298{\%}3A5{\%}3C391{\%}3A{\%}3AAID-HEC457{\%}3E3.0.CO{\%}3B2-7",
language = "English",
volume = "8",
pages = "391--402",
journal = "Health Economics",
issn = "1057-9230",
publisher = "Wiley",
number = "5",

}

A model for the Dutch pharmaceutical market. / Canton, E.J.F.; Westerhout, Ed.

In: Health Economics, Vol. 8, No. 5, 08.1999, p. 391-402.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - A model for the Dutch pharmaceutical market

AU - Canton, E.J.F.

AU - Westerhout, Ed

PY - 1999/8

Y1 - 1999/8

N2 - This paper develops a general‐equilibrium model for the Dutch pharmaceutical market. The model derives the behaviour of patients, pharmacists, drug producers and parallel‐importers from microeconomic principles and recognizes the interactions between the various actors. The latter is important since the general‐equilibrium effects are sometimes at odds with intuition from a partial‐equilibrium approach. A calibrated version of the model is used to evaluate the effects of various policy experiments on the bill for pharmaceutical care in the Netherlands. These experiments include an incentive policy to encourage cost‐conscious drug distribution, an increase of copayments for pharmaceutical care, a reduction of trade barriers for parallel‐importers, and market entry by producers of generic substitutes.

AB - This paper develops a general‐equilibrium model for the Dutch pharmaceutical market. The model derives the behaviour of patients, pharmacists, drug producers and parallel‐importers from microeconomic principles and recognizes the interactions between the various actors. The latter is important since the general‐equilibrium effects are sometimes at odds with intuition from a partial‐equilibrium approach. A calibrated version of the model is used to evaluate the effects of various policy experiments on the bill for pharmaceutical care in the Netherlands. These experiments include an incentive policy to encourage cost‐conscious drug distribution, an increase of copayments for pharmaceutical care, a reduction of trade barriers for parallel‐importers, and market entry by producers of generic substitutes.

U2 - 10.1002/%28SICI%291099-1050%28199908%298%3A5%3C391%3A%3AAID-HEC457%3E3.0.CO%3B2-7

DO - 10.1002/%28SICI%291099-1050%28199908%298%3A5%3C391%3A%3AAID-HEC457%3E3.0.CO%3B2-7

M3 - Article

VL - 8

SP - 391

EP - 402

JO - Health Economics

JF - Health Economics

SN - 1057-9230

IS - 5

ER -